
    
      To explore the novel combination of sirolimus and mycophenolate mofetil (MMF) as
      graft-vs-host disease (GvHD) prevention in human leukocyte antigen (HLA)-matched related
      donor peripheral blood stem cell (PBSC) or marrow transplantation (BMT), collectively
      hematopoietic stem cell transplantation (HSCT). This study will report the toxicities
      associated with this drug combination.

      For all treatments and procedures, Study Day is based on the day of HSCT as Day 0.
    
  